Why Rhythm Pharmaceuticals Stock Triumphed on Tuesday

Rhythm Pharmaceuticals (NASDAQ: RYTM) was a healthcare company perfectly in tune with investor goals on Tuesday. Shares of the commercial-stage biotech soared to close almost 8% higher in value, thanks to a very well-received quarterly earnings report. Rhythm, which rose to prominence thanks to its highly specialized weight-loss drug Imcivree, reported its first-quarter results that morning. Thanks to Imcivree, its only Food and Drug Administration (FDA)-approved product, its revenue nearly doubled year over year. It came in at $60.1 million, compared with $32.7 million in the first quarter of 2025. The consensus analyst estimate was $57 million. Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool